A group of experts has assessed that Comirnaty, the COVID-19 vaccine developed by Pfizer and BioNtech, is effective enough to receive approval for mass distribution..
The Ministry of Food and Drug Safety said on Tuesday that the assessment was made during a meeting of a seven-member advisory panel.
The panel studied the safety and effectiveness of the vaccine by going over the results of clinical trials conducted in six countries, including the U.S. Of the 43-thousand-448 people who took part in the trials, nearly 22 percent were 65 or older.
The panel determined that the vaccine is 95 percent effective in all ages, including teenagers aged 16 and 17 and seniors aged 65 or older.
The Pfizer vaccine is set to go through three rounds of reviews from outside experts, starting with the advisory panel. Pfizer Korea filed for authorization on January 25.